Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS: SEPTEMBER ISSUE PUBLISHED
  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.

Abstract

EXPERIMENTAL BENEFIT OF NEBIVOLOL ON METABOLIC CHANGES ASSOCIATED WITH METABOLIC SYNDROME IN FRUCTOSE-FED RATS

Abdulrahman M. Alahdal, Ameen M. Almohammadi, Ahmed A. Elberry*, Ahmed O. Noor, Diena M. Almasri, Alaa A. Bagalagel and Mahmoud A. Abdel-Hameed

ABSTRACT

The aim of the present study was to investigate the possible effect of nebivolol on metabolic changes associated with the fructose-induced metabolic syndrome in rats. The experimental design consisted of a pretreatment phase for 4 weeks followed by a treatment phase for another 4 weeks. During the pretreatment phase, 10 rats were fed a chow diet (control group), and 20 rats were fed a 20 % w/v highfructose diet (fructose-fed group, FFR) to induce metabolic abnormalities. During the treatment phase, the control group was fed the same chow diet for a further 4 weeks, while, the FFR rats were divided into 2 subgroups. One subgroup of the FFR rats (n=10) was fed a 20% fructose diet alone for further 4 weeks, while the other subgroup (n=10) was fed 20% fructose diet in combination with Nebivolol (2 mg/kg once daily orally) for further 4 weeks. At the end of experimental period (8 weeks), it was found that FFR rats that received fructose alone showed the expected metabolic abnormalities found in the metabolic syndrome. These changes include excessive body weight, impaired glucose tolerance, dyslipidemia, and high blood uric acid levels. These changes were ameliorated in the nebivolol-treated. In conclusion, the results obtained in the current study suggest the possible therapeutic role of nebivolol regarding the metabolic changes associated with metabolic syndrome.

Keywords: .


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More